Henry McCusker

Long/short equity, special situations, contrarian
Henry McCusker
Long/short equity, special situations, contrarian
Contributor since: 2011
Company: Scimitar Equity-Regenerative Medicine Investors
You should have recognized the warnings and red flags, a lot earlier as the share never went anywhere and management continued to take down huge salaries as well as the operating expense issues. Pronouncing a "body" dead after it has been "rotting" in a shallow grave has relegated analysis as bad as the empty shell Nuo has become!
A "joke" was played on investors ... it was embarrassing and should have been cancelled if the management couldn't answer questions from those investors who have waited ... for this company ... so long! At least the CEO could have better read .. his script with out stumbling on product and pipeline particulars.
Pluristem – check your rear-view mirror – why did so many “opine” and react to the Bloomberg article? In the cell therapy universe, PSTI’s more than often “hyperbole” style has by turns been admired and derided. The “walls of reality” closed in … does this “on slot” of written matter talk about their relationships to the “street” and to the reporting thus, “transparency” is the ultimate vehicle … no matter what one does – there is a population of investors that are “moved” by perception! Maybe, there is a lesson here but, the damage is done!
I agree whole heartedly but, KOOL suffers from visibility problems ...
Henry